Baxter International reported second-quarter 2026 results showing revenue growth and higher earnings versus the year-ago quarter, supported by volume gains in Infusion Therapies and Advanced Surgery.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$2.96B$2.81B5.3% | Net income²$126M$91M38.5% | Diluted EPS³$0.24$0.1833.3% |
¹ Reported as “Net sales”. ² Reported as “Net income (loss) attributable to Baxter stockholders”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by Infusion Therapies and Advanced Surgery volume gains; Advanced Surgery rose about 12% in the quarter.
- Reporting was reorganized to two segments with Pharmaceuticals folded into Infusion Therapies & Platforms.
- Launched a new operating model, the Baxter Growth & Performance system, alongside enterprise transformation initiatives.
- Supply constraints and a Novum LVP distribution hold weighed on pump and injectables volumes despite overall sales gains.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.